LUCD
Lucid Diagnostics Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
10.63
P/S
0.02
EV/EBITDA
614.66
DCF Value
$-17,450.79
FCF Yield
-40.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
-0.1%
Operating Margin
-1.1%
Net Margin
-1.2%
ROE
-591.1%
ROA
21.1%
ROIC
-0.1%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $4.70B | $-16.3M | $-0.12 |
| FY 2025 | $4.71B | $-58.0M | $-0.69 |
| Q3 2025 | $1.2M | $-10.4M | $-0.10 |
| Q2 2025 | $1.2M | $-4.4M | $-0.08 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllLatest News
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.25
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.